GUILDFORD, UNITED KINGDOM--(Marketwired - Jan 26, 2017) - (
AIM: AGL and OTCQX: ANPCY
ANGLE plc
("ANGLE" or "the Company")
Interim Results for the six months ended 31 October 2016
OVARIAN CANCER CLINICAL STUDIES PROGRESSING WELL
ANGLE plc (
Operational Highlights
Financial Highlights
Garth Selvey, Chairman, commented:
"The Parsortix system is now delivering early adoption revenues with increasing sales for research use. Our two major ovarian cancer studies are progressing towards completion by mid-year and data from the initial patient cohort is positive.
We have also continued to work hard towards obtaining FDA clearance of the system. Our sustained efforts have resulted in detailed analytical and clinical study plans. The analytical study is in progress and the clinical study plan has recently been submitted to three world-leading US cancer centres for formal scientific committee review.
There is still much to do, but the goal remains to layer additional supportive scientific data from clinical studies incorporating Parsortix use on top of our hard-won reputation in the international research environment. This, we believe, is the gateway to competing effectively in a very large and growing liquid biopsy market."
Analyst meeting and webcast details
A meeting for analysts will be held at 10:30 am on 26 January 2017 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD. Please contact FTI Consulting on 020 3727 1000 for details.
To listen to the live webcast of the analyst meeting, please see
http://www.angleplc.com/investor-information/investor-centre/ for details.
1 European Association for Cancer Research (EACR 2016); American Association for Clinical Chemistry (AACC 2016); the National Cancer Research Institute (NCRI 2016); San Antonio Breast Cancer Symposium (SABC 2016)
For further information:
ANGLE plc | 01483 685830 | |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
||
Cenkos Securities Stephen Keys (Nominated adviser), Steve Cox Russell Kerr (Sales) |
020 7397 8900 | |
FTI Consulting Simon Conway, Mo Noonan Kimberly Ha (US) |
020 3727 1000 001 212 850 5612 |
|
These Interim Results may contain forward-looking statements. These statements reflect the Board's current view, are subject to a number of material risks and uncertainties and could change in the future. Factors that could cause or contribute to such changes include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Group's research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group's products by customers.
Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/1509V_1-2017-1-25.pdf
This information is provided by RNS
The company news service from the London Stock Exchange
Contact Information:
Contact:
RNS
Customer Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com